The Role of Opioid Receptor Phosphorylation and Trafficking in Adaptations to Persistent Opioid Treatment

Emma E. Johnson  MacDonald J. Christie  Mark Connor
Pain Management Research Institute, Kolling Institute, University of Sydney at Royal North Shore Hospital, St. Leonards, Australia

Introduction

Opioid receptor activation is the mainstay of clinical analgesia and the central event in the abuse of narcotics. Continued opioid use produces tolerance to the acute effects of the drug and adaptations that lead to physical and psychological dependence. Continued μ-receptor signaling provides the engine for these adaptations, with most evidence suggesting that chronic agonist treatment produces only limited alterations in primary μ-opioid receptor signaling. Here we examine agonist regulation of μ-opioid receptor function, and whether this is altered by chronic treatment. Receptor phosphorylation is thought to be the key initial event in agonist regulation of the μ-opioid receptor, providing a signal for acute receptor desensitization and also subsequent receptor resensitization. Morphine appears to produce qualitatively and quantitatively different μ-receptor phosphorylation than other agonists, but the consequences of this remain obscure, at least in neurons. There is no evidence that agonist-induced μ-opioid receptor phosphorylation changes in chronically morphine-treated animals, although receptor regulation appears to be altered. Thus, as receptor phosphorylation and resensitization appear to maintain continued signaling through the μ-opioid receptor, these two events are crucial in facilitating adaptations to chronic opioid treatment, and the possibility that agonist-specific phosphorylation can contribute to the development of different adaptations remains open.

Key Words
Opioid receptor trafficking · Phosphorylation · G-Protein-coupled receptor kinase · Morphine, chronic

Abstract
μ-Opioid receptor activation underpins clinical analgesia and is the central event in the abuse of narcotics. Continued opioid use produces tolerance to the acute effects of the drug and adaptations that lead to physical and psychological dependence. Continued μ-receptor signaling provides the engine for these adaptations, with most evidence suggesting that chronic agonist treatment produces only limited alterations in primary μ-opioid receptor signaling. Here we examine agonist regulation of μ-opioid receptor function, and whether this is altered by chronic treatment. Receptor phosphorylation is thought to be the key initial event in agonist regulation of the μ-opioid receptor, providing a signal for acute receptor desensitization and also subsequent receptor resensitization. Morphine appears to produce qualitatively and quantitatively different μ-receptor phosphorylation than other agonists, but the consequences of this remain obscure, at least in neurons. There is no evidence that agonist-induced μ-opioid receptor phosphorylation changes in chronically morphine-treated animals, although receptor regulation appears to be altered. Thus, as receptor phosphorylation and resensitization appear to maintain continued signaling through the μ-opioid receptor, these two events are crucial in facilitating adaptations to chronic opioid treatment, and the possibility that agonist-specific phosphorylation can contribute to the development of different adaptations remains open.

Introduction

Opioid receptor activation is the mainstay of clinical analgesia and the central event in the abuse of heroin and other narcotics. Of the four identified G protein-coupled opioid receptors, it is the μ-opioid receptor that is the primary target of analgesics and drugs of abuse. The underlying mechanisms of opioid tolerance and dependence are not fully established, although these phenomena are known to involve adaptations at opioid-sensitive synapses and in opioid-sensitive neural circuits [1–5; for review of early studies see 6]. There is also increasing evidence that δ- and κ-opioid and ORL-1 receptor systems are important for modulating the acute effects of μ-opioid receptor activation, as well as being critical for some of the adaptations that accompany prolonged μ-opioid agonist...
mostly of the G_i/o subclass [11], although as demonstrat-
and G proteins, and reviews of the adaptations in signaling molecules
downstream of opioid receptors can be found elsewhere
[6, 10].

**Opioid Receptor Signal Transduction**

**Activation**

Opioid receptors signal via activation of heterotrimer-
ic guanine nucleotide-binding proteins (G proteins), mostly of the G_{i/o} subclass [11], although as demonstrat-
ed for other G protein-coupled receptors (GPCRs), non-
G protein-mediated signal transduction by opioid recep-
tors may also be possible [12]. In the absence of ligands, opioid receptors exhibit basal constitutive activity [13, 14] but agonist occupation induces a dramatic increase in receptor-stimulated G protein turnover. The activated G protein subunits couple to many well-characterized effectors including adenylyl cyclase, mitogen-activated protein kinases, voltage-gated calcium channels and G protein-activated potassium channels. When the opioid agonist is removed, receptors no longer efficiently activate G proteins and the heterotrimeric G proteins reform, effectively ending any further input from the opioid receptors. While this is likely to produce an abrupt end to signal-
nered via G protein subunits (i.e. millisecond deactivation of G protein-gated inward rectifier potassium channels [15]), the effects of opioid exposure may persist for some time in second-messenger-regulated protein kinase cascades. In these respects, opioid recep-
tors are similar to many other GPCRs and the mecha-
nisms which regulate the activity of other GPCRs are also likely be involved in the regulation of opioid receptor ac-
tivity.

**Acute Desensitization**

When opioid agonist exposure persists beyond a few seconds, it is often possible to detect a decline in the opioid-stimulated response, termed acute desensitization [for review see 16]. In systems where desensitization can be measured rapidly and precisely, μ-opioid receptor sig-
aling is abrogated within 3–5 min, and it recovers over
about 30 min (fig. 1). Desensitization is observed for
many GPCRs, and it can involve changes in the receptors
or signaling proteins and effector molecules [17, 18]. The
most well-characterized desensitization processes invol-
volving the receptors themselves are an acute disruption of
the capacity of the receptors to interact with G proteins
or a sequestration of the receptors away from the cell sur-
face. Opioid receptors are not thought to signal once re-
moved from the cell surface, and the protein–protein in-
teractions necessary for recruitment of opioid receptors
to internalization pathways are likely candidates for
blocking further receptor interactions with G proteins,
thus providing a potential explanation for acute opioid
receptor desensitization [19].

**Desensitization Mechanisms Not Involving Receptor Phosphorylation**

The focus of this review is the potential role of receptor phosphorylation and trafficking in regulating opioid receptor signaling, but other mechanisms of modulating opioid receptor signaling have been proposed. The most
heavily studied of these involve regulators of G protein-
signaling (RGS) proteins, which modify GPCR signaling
in various ways [for review see 20, 21]. Different RGS
proteins have been suggested to acutely regulate μ-opioid
receptor signaling in vivo by acting as GTPase-activating
proteins to accelerate the termination of μ-opioid recep-
tor signaling as well as acting in the longer term (hours)
by binding the G protein α subunits required for μ-opioid
receptor signaling [22]. Mice lacking RGS9 are more sen-
tive to the acute rewarding and analgesic actions of mor-
phine, and apparently develop more intense physical de-
pendence but proportionally less analgesic tolerance to
the drug [23]. The role of RGS proteins in opioid recep-
tor desensitization has not been directly examined in sin-
gle neurons.

**Phosphorylation and Receptor Regulation**

Many of the processes that can lead to GPCR desen-
sitization involve a change in the phosphorylation state
of the receptors, usually an increase in the number of phosphate groups per receptor. Many GPCRs are ba-
sally phosphorylated on serine (Ser), threonine (Thr) or
tyrosine (Tyr) residues, and ligand-activated receptors
can be further phosphorylated by specific GPCR kinas-
es (GRKs) or second-messenger-dependent protein ki-
nases. Receptor phosphorylation can provide binding
sites for adaptor or uncoupling molecules such as arres-
tins [24], it can block the interaction of proteins with
previously accessible regions of the receptor and change the types of G protein the receptor interacts with [12, 25].

A very common pathway of GPCR regulation that is usually initiated by agonist exposure is receptor internalization, which is an example of receptor trafficking. This process has been best defined for the β-adrenergic receptor. It is initiated by receptor phosphorylation, proceeds via removal of the receptor from the cell surface through clathrin-dependent endocytosis and finishes with the recycling of the dephosphorylated receptor to the cell surface or degradation of the receptor in lysosomes. The signal for receptor internalization is usually provided by multiple phosphorylation of the agonist-occupied receptor by GRKs, these phosphate groups provide a binding site for arrestin, an adaptor protein that acts as a scaffold for the proteins involved in recruiting the receptor to the clathrin pathway [24].

Although there are pathways for GPCR trafficking currently being defined that do not appear to involve GRKs, arrestin or clathrin-mediated endocytosis [24], the present consensus is that opioid receptors are desensitized and internalized in a manner analogous to β-adrenergic receptors. In the next section we will review the evidence for this, focusing particularly on the evidence for the role of opioid receptor phosphorylation in these processes.

**Opioid Receptors Are Phosphoproteins**

There are approximately 20 phosphorylation sites on various Ser, Thr and Tyr residues on the μ-opioid receptor in regions conceivably accessible to protein kinases [26]. These sites are located on all three cytoplasmic loops....

---

**Fig. 1.** A diagram outlining the basic processes involved in the regulation of μ-opioid receptors in response to acute agonist exposure. More details of these processes can be found in the text. A Morphine-activated receptors desensitize quite rapidly and resensitize relatively slowly and incompletely [63, 71]. Morphine-activated receptors are phosphorylated on Ser^{375} [28], perhaps by a GRK, and may also be phosphorylated by Ca^{2+}-dependent protein kinase (PKC) [49]. Morphine-induced μ-opioid receptor internalization has been observed in some neurons [65, 66] but not others [52, 59]. B Agonists such as DAMGO (and etorphine) generally produce a rapid and more complete desensitization of cellular responses than morphine. This acute desensitization reverses within about 20 min in neurons [76, 88]. These agonists induce more phosphorylation of the μ-opioid receptor than morphine [28, 35] and there is rapid and robust internalization and recycling of the μ-receptor in all systems examined.
of the receptor and on the intracellular carboxyl tail. Very few studies have established unequivocally which of these potential sites are phosphorylated. Phosphopeptide mapping showed that agonist-induced phosphorylation of rat μ-opioid receptors expressed in HEK293 cells occurred exclusively within a region encompassing the final two transmembrane domains and intracellular tail of the receptor [27]. A phosphopeptide-specific antibody has been used to demonstrate agonist-induced increases in phosphorylation of the intracellular tail residue Ser375 in the μ-opioid receptor [28]. All other studies of opioid receptor phosphorylation have relied on measurements of total receptor phosphorylation and the use of mutant receptors lacking various potential phosphate acceptor sites. This can be problematic because it is difficult to establish whether a change in overall receptor phosphorylation occurs because the mutated phosphorylation sites were truly phosphoacceptor residues, or whether they formed parts of binding sites for protein kinases or other regulatory molecules. There are many unresolved discrepancies regarding the role of phosphorylation of different residues in opioid receptors that have arisen from deletion and mutagenesis studies. The discrepancies between studies probably reflect the different repertoires of protein kinases and other regulatory molecules found in different expression systems, as it has been shown that the cellular environment can determine the phosphorylation pattern of β2-adrenergic receptor [29, 30]. Small differences between the sequences of rodent and human receptors may also contribute.

Basal Phosphorylation

μ-Opioid receptors in native tissue [31] and heterologous systems are constitutively phosphorylated [27, 28, 32–40], as measured by incorporation of 32P into unstimulated cells. Information about the kinases responsible for agonist-independent phosphorylation or the role of constitutive phosphorylation in modulating μ-opioid receptor function is limited, although it has been reported that basal (and agonist-stimulated) μ-opioid receptor phosphorylation could be prevented by the protein kinase inhibitor H7, but not a panel of related inhibitors [34]. Basal μ-opioid receptor phosphorylation is increased by activators of Ca2+-dependent protein kinase [33, 39] or by co-incubation with the catalytic subunit of protein kinase A [41]. It has been suggested that phosphorylation of some Ser/Thr residues in the carboxyl terminal domain of the μ-opioid receptor may act as a signal to impair receptor trafficking [27], and that phosphorylation of Tyr residues in the 1st and 2nd intracellular loops of the μ-opioid receptor may regulate signaling efficacy [42], these intriguing possibilities deserve more attention.

Agonist-Induced Phosphorylation

μ-Opioid receptor phosphorylation following agonist exposure is rapid, with a substantial increase in basal levels detectable only a few minutes after agonist exposure and maximal incorporation of 32P usually occurring after 10–15 min in native and recombinant receptors [28, 31, 33, 36, 37, 39]. Site-directed mutagenesis experiments have suggested many amino acid residues in the μ-opioid receptor which may be phosphorylated following agonist exposure, including Ser and Thr residues in the carboxy-terminal tail as well as Tyr residues scattered throughout the protein. However, only Ser375 of the rat μ-opioid receptor has been definitively demonstrated to be phosphorylated in response to agonist treatment, this was done using a specific antibody generated to phosphoserine375 [28]. Ser375 was reported to be minimally phosphorylated in unstimulated HEK293 cells, but exposure to a variety of μ-opioid receptor agonists produced a rapid increase in phosphorylation of the residue. The agonist-induced increase in phosphoserine375-like immunoreactivity was also observed when μ-opioid receptors were transfected into embryonic cortical neurons [28]. Morphine exposure generally results in less phosphorylation of μ-opioid receptors than other, more efficacious agonists, and recent experiments indicate that this may be because different agonists can promote phosphorylation of different residues. In the study by Schulz et al. [28], morphine produced a significant increase in Ser375 phosphorylation, although the increase was only about 35% of that produced by the Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol enkephalin (DAMGO), sufentanil or etorphine. This is consistent with data from most previous studies [28, 31–33, 35], although some studies have reported that morphine did not produce any increase in phosphorylation of the μ-opioid receptor [36, 37]. Notably, mutation of Ser375 to Ala essentially abolished morphine-induced μ-opioid receptor phosphorylation but only reduced DAMGO-induced phosphorylation by about 50% [28]. This strongly suggests that DAMGO exposure causes a qualitatively and not just quantitatively different phosphorylation pattern to morphine, although the additional residue(s) phosphorylated in response to DAMGO have not been identified. Conversely, when purified μ-opioid receptors are co-incubated with the catalytic subunit of PKA, morphine but not DAMGO promotes substantial phosphorylation of the receptor at unidentified residues [41].
The kinases responsible for agonist-induced phosphorylation of μ-opioid receptors have not been definitively established. Overexpression of GRK2 or GRK3 has been repeatedly shown to produce an increase in μ-opioid receptor phosphorylation in response to agonist exposure [28, 36, 39], including phosphorylation of Ser375. In an elegant experiment, an GRK2 enzyme was genetically engineered to be susceptible to a small molecule inhibitor and co-expressed with μ-receptors in HEK293 cells [44]. While available data suggest that GRKs can phosphorylate the molecular weak interaction between engineered GRK2 [43] . Other evidence indicates a relatively weak interaction between μ-opioid receptors and GRKs. In particular, agonist stimulation of μ-opioid receptors did not recruit fluorescently tagged GRK2 or 3 to the plasma membrane of HEK293 cells [44]. While available data suggest that GRKs can phosphorylate μ-opioid receptors, strong evidence that they do so in native neurons is lacking.

**Opioid Receptor Dephosphorylation**

The protein(s) involved in dephosphorylation of μ-opioid receptors are unknown. An early study reported that morphine-induced phosphorylation of human μ-opioid receptor in Chinese hamster ovary cells was reversed in about 30 min [35]. By contrast, Schultz et al. [28] reported differential dephosphorylation of Ser375 in rat μ-opioid receptor expressed in HEK293 cells after phosphorylation induced by morphine or DAMGO exposure. The phosphorylation resulting from DAMGO exposure reversed within about 60 min of DAMGO removal, while that produced by morphine did not apparently reverse after 6 h of being morphine-free. Dephosphorylation of several Tyr residues has been suggested to regulate μ-opioid receptor agonist efficacy in Xenopus oocytes, but this was not directly demonstrated [42], and has not been shown in neurons.

**Functional Consequences of Changes in Receptor Phosphorylation**

It is generally assumed that increased receptor phosphorylation is involved in the acute desensitization and trafficking of opioid receptors and the role of receptor phosphorylation in regulating receptor activity during chronic agonist treatment has also received significant experimental attention. However, in direct contrast to these ideas, it has been proposed that agonist-induced μ-opioid receptor phosphorylation promotes an increase in the constitutive activity of the receptor, such that it signals effectively in the absence of agonists [for review see 45]. The site of this phosphorylation has not been established, although it is suggested to be in the 3rd intracellular loop of the receptor, close to a putative calmodulin-binding motif. The kinase(s) responsible for this putative phosphorylation have not been identified, and increases in basal μ-opioid receptor activity have not been demonstrated in intact neurons, but a role for increased constitutive receptor activity in chronically morphine-treated animals has been proposed (see below).

**Acute Desensitization**

The role of phosphorylation in acute opioid receptor desensitization has been difficult to define for several reasons. These include the lack of selective reagents for the protein kinases likely to be involved in receptor phosphorylation and the limitations of many of the biochemical assays used to detect a loss of receptor activity [for review see 16]. However, it is clear that acute μ-opioid receptor desensitization can proceed with a time course similar to that of agonist-induced receptor phosphorylation, i.e. <5 min [28, 31, 33, 39].

Opioid receptor phosphorylation may promote desensitization in several ways. Firstly, receptor phosphorylation could directly interfere with the interaction of receptors with G proteins, and many of the putative phosphorylation sites in opioid receptors are in the regions of the receptor likely to be involved in G protein binding. Receptor phosphorylation can inhibit receptor–G protein interactions [12, 46] although there is no direct evidence for this for opioid receptors. Alternatively, phosphorylation of receptors can provide a binding site for other proteins that prevent receptor–G protein interaction. One such protein is arrestin, a multifunctional adaptor protein that binds with high affinity to phosphorylated, agonist-occupied GPCR [47, 48]. Two variants of arrestin, arrestin2 and arrestin3, are expressed ubiquitously in the brain. Arrestin binding alone is likely to block interactions of opioid receptors with G proteins [49], but arrestin binding is also crucial for recruiting GPCR to clathrin-dependent endocytotic pathways, and once removed from the cell surface there is no evidence that μ-opioid receptors continue to signal.

High-affinity arrestin binding to GPCR is associated with an agonist-occupied receptor that has been multiply phosphorylated [48]. Some studies have indicated that agonist-induced phosphorylation of the μ-opioid receptor may involve multiple residues, consistent with formation of high-affinity arrestin-binding sites. The protein kinases most commonly associated with opioid receptor
phosphorylation leading to arrestin binding are the GRKs. While there are no specific inhibitors of native GRKs, GRK3 knockout mice have been used to explore the role of this protein in μ-opioid receptor regulation. The desensitization of fentanyl- and morphine-induced population spike facilitation in the hippocampus was significantly attenuated in GRK3 null mice, providing strong indirect evidence for the involvement of this kinase in short-term regulation of μ-opioid receptor signaling [50]. Activation of protein kinase C also facilitates rapid μ-opioid receptor desensitization in neurons [49], perhaps by providing some of the phosphate groups required for arrestin binding.

The evidence that agonist activation of the μ-opioid receptor promotes arrestin binding to the receptor is indirect. The most striking evidence comes from studies in cells heterologously expressing μ-opioid receptors and fluorescent arrestin constructs which showed that cytosolic arrestin3 moves to the vicinity of the cell surface when receptors are stimulated with a variety of agonists [36, 37, 51, 52]. Early experiments suggested that μ-opioid receptor activation only recruited arrestin3, although a recent study indicated that under some circumstances arrestin2 might also be recruited [53]. Arrestin translocation is facilitated by subunits released from G protein heterotrimers, and so, strictly speaking, arrestin translocation may simply reflect receptor activation and not receptor phosphorylation. Mice with a genetic deletion of arrestin3 have enhanced signaling compared with wild-type animals, reflected in greater agonist-stimulated GTPγS binding [54–56]. The contribution of receptor desensitization during the GTPγS assay itself to the final measurement of receptor activity is unknown, so it is not clear whether the apparently enhanced coupling reflects a lack of intra-assay desensitization or an enhanced basal μ-opioid receptor coupling. μ-Opioid receptor desensitization or trafficking has not been examined at the cellular level in either arrestin3 or GRK3 null mice.

Receptor Trafficking

The movement of μ-opioid receptors into clathrin-dependent endocytic pathways following agonist binding has been observed in many different expression systems, and is prima facie evidence for agonist-dependent receptor phosphorylation and subsequent arrestin binding, even though the details of the kinases and phosphorylation sites involved are still far from defined. Examining trafficking of opioid receptors in neurons has proved more difficult. An increase in intracellular μ-opioid receptor-like immunoreactivity has been repeatedly shown after exogenous agonist exposure or a physiological stimulus [57–59] both in vivo and in cultured neurons, and the internalization of fluorescent opioid agonists in cultured neurons has also been reported [60]. Interestingly, in contrast to studies of μ-opioid receptors heterologously expressed in HEK293 or AtT-20 cells [32, 61–64], morphine is as efficient as DAMGO at promoting internalization of epitope-tagged μ-receptors in cultured striatal neurons [65]. μ-Opioid receptors heterologously expressed in hippocampal neurons do not internalize in response to morphine [52] and morphine only produces internalization of μ-receptors in the dendrites of cultured nucleus accumbens neurons [66]. Thus local concentrations of protein kinases and arrestins may determine the fate of morphine-activated μ-receptors in neurons, although it has not been possible to identify specific differences in GRK and/or arrestin expression or subcellular localization between neurons that will internalize μ-opioid receptors in response to morphine and those which will not. The absence of significant morphine-induced internalization of the μ-receptor in non-neuronal cells has been attributed to these cells expressing reduced levels of appropriate kinases or arrestins [65], or perhaps that other as yet unidentified molecules are required for most efficient receptor trafficking. While it is assumed that trafficking of native μ-opioid receptors involves the same processes of rapid receptor phosphorylation and arrestin binding as have been shown in heterologous expression systems, direct evidence for this is sparse. Importantly, significant internalization of μ-opioid receptors occurred during application of analgesic doses of DAMGO to the dorsal horn of the spinal cord, indicating that receptor trafficking did not terminate effective receptor signaling [58].

Resensitization

The presumed link between μ-opioid receptor internalization and desensitization has led to the idea that μ-opioid receptor recycling to the cell surface is a major mechanism for the resensitization of receptor signaling [19, 67–69]. The existence of a specific pathway for μ-opioid receptor recycling has been identified [68], and it is presumed that the μ-opioid receptor is dephosphorylated somewhere during this process. However, as outlined above, phosphatases responsible for μ-opioid receptor dephosphorylation have not been identified, and there is no direct evidence that recycled μ-opioid receptors have fewer phosphorylated residues, or that any phosphates presumably removed during the trafficking process are those added in response to agonist. Intriguing
evidence has been provided suggesting that µ-opioid receptors that have undergone one round of receptor trafficking and been reinserted in the plasma membrane are not in the same state as they were before agonist application. Using a genetically engineered GRK2 construct, it was shown that blocking the activity of over-expressed GRK2 prevented initial morphine-induced internalization of µ-opioid receptors [43]. However, continued blockade of this enzyme did not prevent the re-internalization of receptors that occurred in the continued presence of morphine, suggesting that GRK2 was not involved in this process [43]. Whether recycled receptors have fewer or different phosphorylated residues from receptors that have not been exposed to morphine remains to be established.

**Phosphorylation, Desensitization and Trafficking in Opioid Tolerance and Adaptation**

Because receptor tolerance and opioid-induced neuronal adaptations occur after acute receptor desensitization, it is tempting to speculate that mechanisms of acute receptor regulation might be linked to the induction or maintenance of long-term tolerance and adaptation. In particular, a key role for the process of receptor trafficking in the induction of tolerance and neuronal adaptations has been proposed by many investigators, and despite broad agreement about the biochemical mechanisms of desensitization, trafficking and receptor resensitization, the significance of these events has been hotly debated (fig. 2).
The Role of Trafficking in Regulating μ-Opioid Receptor Signaling

There are two competing ideas regarding the role of μ-opioid receptor trafficking in the induction or maintenance of long-term tolerance and adaptation. One hypothesis is that the internalization of μ-opioid receptors terminates signaling and retards the development of adaptations to prolonged opioid exposure [59, 70]. According to this idea the relative inability of morphine to recruit μ-opioid receptors continues to signal on the cell surface and thus activate adaptive processes. The main problem with this idea is that it assumes that μ-opioid receptors which recycle during continuous exposure to agonists, such as methadone or enkephalin, are somehow unable to activate adaptive processes despite a continuous signal being provided by newly reinserted μ-opioid receptors. There is no evidence for a different kind of signaling from uninternalized, morphine-activated μ-opioid receptors and recycled agonist-activated receptors, although there is indirect evidence to suggest that these receptors may not be operationally identical [45]. Evidence for a differential induction of adaptations in HEK293 cells after chronic treatment with internalizing and non-internalizing agonists is conflicting, with some studies finding a greater superactivation of adenylyl cyclase with morphine [59, 70], and others reporting greater superactivation with DAMGO [69]. The theory as originally proposed also assumes that morphine does not induce significant receptor desensitization or internalization in neurons, assumptions which recent evidence suggests are unwarranted [65, 66, 71]. Some of the key observations of this theory have not been confirmed by other investigators [69, 72, 73].

The second hypothesis linking μ-opioid receptor trafficking to tolerance suggests that profound tolerance to morphine occurs because unrecycled receptors remain uncoupled, while receptors activated by other agonists recycle and can thus maintain signaling [36, 40, 67, 69]. This theory has been recently extended to include the notion that the continued signaling produced by recycled receptors recruits cellular adaptations more efficiently than signaling from uninternalized, desensitized receptors. This idea also means that receptor tolerance and cellular adaptations may be separable; i.e. morphine may produce tolerance without much adaptation while a drug, such as fentanyl or methadone, would produce less loss of receptor function but more adaptive changes [69]. This theory seems to be at odds with available evidence indicating that μ-opioid receptor tolerance measured at the cellular level in morphine-treated animals is modest [74–77], while neuronal adaptations in the same animals are profound [1, 3, 6, 78]. However, only changes associated with chronic morphine treatment have been assessed at the cellular level, and it remains to be established whether these differ quantitatively or qualitatively from those produced by agonists such as methadone or fentanyl.

Both hypotheses have some experimental support from in vitro experiments with heterologously expressed μ-receptors, but they have never been directly tested on neurons. Further, neither hypothesis has really been tested beyond about 24 h in vitro, far shorter than in vivo opioid exposures that produce profound tolerance and adaptations. In the remainder of this review we will consider the evidence for changes in opioid receptor signaling and regulation during chronic agonist treatment, and whether these can be related to changes in opioid receptor phosphorylation.

How Does Signaling Change in Chronically Agonist-Treated Animals?

In studies that have examined μ-opioid receptor responses in isolation from the adaptations produced by chronic morphine treatment, μ-opioid receptor signaling is only modestly reduced. Cellular responses of neurons to efficacious agonist are usually barely altered, while responses to partial agonists such as morphine are more strongly affected, but substantial signaling capacity still remains [1, 3, 74–77]. Some studies of μ-opioid receptor activation of G proteins in chronically morphine-treated animals have shown substantial attenuation of signaling [55], but most have reported modest decreases or little change [79–81]. There are few studies of opioid receptor signaling following chronic treatment of animals with agonists other than morphine, but intrathecal treatment with DAMGO, endomorphin-1 and endomorphin-2 all reduced μ-receptor activation of G proteins in the mouse spinal cord [82].

Studies in cell lines [83, 84] and mice [45, 85] have demonstrated an apparent increase in constitutive μ-opioid receptor activity following treatment with morphine or other μ-opioid receptor agonists. This increase in agonist-independent activity is inferred by an increase in the amount that inverse agonists inhibit basal receptor signaling. It has been suggested, but never proven, that the increases in constitutive activity are mediated by μ-opioid receptor phosphorylation [45]. There is some evidence that constitutively active μ-opioid receptors may preferentially signal to a different subset of G proteins than

Opioid Receptor Phosphorylation, Trafficking and Adaptation

Neurosignals 2005:14:290–302
agonist-activated receptors [83], but no evidence that they recruit different adaptations to continuously agonist-occupied receptors. Perhaps the most intriguing aspect of constitutively active receptors is the very slow time course with which the activity reverses in vivo, which will have the effect of prolonging μ-opioid receptor signaling after agonists have left the tissue [85]. Constitutive μ-opioid receptor activity was not detected at the level of IC₅₀ inhibition in locus ceruleus (LC) neurons from chronically morphine-treated rats [75] or PAG neurons from chronically morphine-treated mice [77], and the cellular consequences of signaling by constitutively active μ-opioid receptors remain unknown.

**μ-Opioid Receptor Phosphorylation in Chronically Agonist-Treated Animals**

μ-Opioid receptors continue to incorporate ³²P in thalamic slices from morphine-tolerant rats, and significant further phosphorylation is stimulated by exposure to DAMGO [31]. Both the basal ³²P incorporation and DAMGO-stimulated phosphorylation are increased in morphine-treated compared with controls. Despite the continued agonist-stimulated receptor phosphorylation, DAMGO inhibition of adenylyl cyclase activity in the same tissue was completely abolished [31], indicating that the receptors were functionally uncoupled, although it was not established if this was due to changes at the level of the μ-opioid receptor or its effectors.

**μ-Opioid Receptor Desensitization Changes in Chronically Agonist-Treated Animals**

Acute desensitization of μ-opioid receptor signaling is altered in chronically morphine-treated animals [71, 76]. In LC neurons, a 10-min application of a high concentration of met-enkephalin (ME) results in a similar decline in the response in cells from vehicle or morphine-treated rats. When the ME challenge is shortened to 2 min, there is still a profound inhibition of the subsequent response to an EC₅₀ concentration of the peptide, which normally recovers completely within 20–25 min. In morphine-treated rats, however, the initial reduction in the LC response to the EC₅₀ concentration of ME is significantly greater and the recovery of this response is significantly reduced at 25 min. Similar observations were made for morphine and morphine-6-glucuronide [71, 76].

**μ-Opioid Receptor-Trafficking Changes in Chronically Agonist-Treated Animals**

μ-Opioid receptor trafficking in chronically morphine-treated animals has only been directly examined in one study [86], although a relative increase in intracellular versus plasma membrane μ-opioid receptor immunoreactivity was found in brainstem neurons from morphine-treated rats [87]. In the study where trafficking was examined there was a significant reduction in DAMGO-mediated anti-nociception in the treated animals but no change in the amount of μ-opioid receptor internalization in response to DAMGO [86]. There was also no difference in the basal amount of intracellular μ-opioid receptor immunoreactivity, despite the continued presence of morphine in the rats. These data suggest that μ-opioid receptors are still trafficked in response to an agonist even though they are presumably less effectively coupled to intracellular effectors. The results also show that chronic morphine has not induced receptor modifications that render receptors resistant to trafficking machinery. It will be fascinating to find out whether the protein kinases involved in facilitating μ-opioid receptor internalization in chronically morphine-treated animals are the same as those involved in naïve animals, particularly in light of the recent suggestion that GRK2 is only involved in the first but not subsequent rounds of μ-opioid receptor trafficking in HEK293 cells [43].

The desensitization and recovery of μ-opioid receptor responses in LC neurons has been attributed to receptor uncoupling followed by internalization and recycling [71, 88], although it has not yet been possible to directly visualize these processes in LC neurons. Monensin, which interferes with receptor recycling to the plasma membrane, increases the steady-state desensitization produced by ME in LC neurons and inhibits μ-opioid receptor recovery from desensitization, implying that relatively rapid receptor trafficking mediates a component of acute μ-opioid receptor desensitization. Monensin still potentiates the initial ME desensitization and further slows the already compromised recovery from desensitization in morphine-treated rats, providing further evidence that receptor-trafficking processes persist in morphine-treated animals [71].

The evidence that reversal of acute μ-opioid receptor desensitization is compromised in LC neurons from morphine-treated rats indicates that there may be an alteration in some aspect of the receptor-trafficking pathway. Changes in the expression of a number of proteins putatively involved in μ-opioid receptor trafficking have been reported in chronically μ-opioid agonist-treated animals, although these changes can be agonist-dependent and are not always observed with morphine treatment [7, 89, 90]. It is not known whether these changes occur in μ-opioid receptor-expressing neurons or other cells that are parts
of neuronal circuits affected by adaptations to chronic μ-opioid receptor agonist treatment. Importantly, because crucial trafficking proteins are utilized by many GPCRs, changes in GRK, dynamin or arrestin levels are likely to affect the regulation of multiple neurotransmitter receptors in opioid-sensitive neuronal circuits. Such changes in the regulation of other GPCRs may be an adaptation to chronic opioid treatment, although there is no direct evidence for this.

**Responses to Chronic Morphine Treatment of Animals Lacking Proteins Involved in μ-Opioid Receptor Trafficking**

GRK3 knockout mice displayed similar anti-nociceptive responses to fentanyl and morphine as wild-type littermates, but tolerance to prolonged treatment with fentanyl (but not morphine) was attenuated [50]. The signs of naloxone precipitated withdrawal from chronic fentanyl treatment were similar in GRK3 null and wild-type mice, implying that adaptations to chronic fentanyl treatment persisted in these animals [48].

Arrestin3 deletion mice are more sensitive to the acute anti-nociceptive and hypothermic effects of morphine and display elevated baseline nociceptive sensitivity in some tests [54, 56]. Arrestin3 knockout animals develop no tolerance to the anti-nociceptive effects of morphine in some behavioral tests while in others the development of tolerance is significantly delayed [54, 56]. However, like the GRK3 knockout mice animals, the arrestin3 null animals display similar signs of naloxone-precipitated withdrawal to chronically treated wild-type mice [55]. The ubiquitous upregulation of adenylyl cyclase activity produced by chronic morphine treatment is also similar in striatal membranes from each genotype of mouse [55]. The anti-nociceptive tolerance to morphine in wild-type mice was accompanied by a complete loss of DAMGO-stimulated G-protein activation in the brain, while there was only a small loss of activity in arrestin3 knockout animals, indicating that arrestin3 deletion prevented uncoupling of μ-opioid receptors [55]. The complete uncoupling of the μ-opioid receptor is difficult to reconcile with the persistence of morphine-induced analgesia in the tolerant animals and is in contrast to previous studies that used much higher doses of morphine in chronic treatment paradigms [1, 71, 74–77, 80, 81]. The apparent complete loss of μ-opioid receptor activity in wild-type mice also begs the question of how receptors which no longer signal to G proteins promote adaptations in adenylyl cyclase as efficiently as those in the arrestin3 knockouts, where receptor signaling is enhanced compared to normal, even after chronic agonist treatment.

Studies to date in GRK3 or arrestin3 knockout mice have not provided a clear test of the hypothesis that μ-opioid receptor phosphorylation and/or trafficking is involved in adaptations to chronic opioid treatment. Most importantly, neither μ-opioid receptor phosphorylation nor trafficking have been directly examined in these animals. These experiments are difficult, but the next most useful experiments, those examining functional responses of single μ-opioid-sensitive neurons, have also not been reported. While it is tempting to speculate that the changes in opioid analgesic tolerance in GRK3 and arrestin3 knockout animals result from changes in μ-opioid receptor function, GRK3 and arrestin3 likely regulate dozens of other GPCRs involved in regulating the activity of opioid-sensitive circuits in mice. Further, the emerging role of arrestins as active transducers of receptor signaling [91] raise the possibilities that the changes observed in both arrestin3 and GRK3 animals result from altered consequences of μ-receptor activation rather than changes in μ-receptor regulation.

**Other Possible Roles of μ-Receptor Phosphorylation and Trafficking in Chronically Opioid-Treated Animals**

In contrast to animals treated with morphine, where changes in μ-receptor amounts are generally modest [92–94], chronic treatment of mice with high-efficacy/high-affinity opioid agonists, such as etorphine or sufentanil, results in a reliable downregulation of μ-opioid receptors [94–96]. Presumably this loss of receptor protein occurs after removal of the receptor from the cell surface by arrestin-dependent trafficking. It is possible that receptor protein is lost through repeated rounds of trafficking in the continued presence of agonist, each round of internalization/recycling resulting in the loss of a small portion of the internalized receptors. In HEK293 cells about 20% of μ-opioid receptors are degraded in lysosomes during each round of trafficking [68], although whether this is the case in neurons is not known. How (or whether) μ-opioid receptors are tagged for degradation rather than recycling is not known, but it is conceivable that agonist-dependent phosphorylation events may signal this – either a greater overall receptor phosphorylation in response to a high-efficacy agonist or phosphorylation of distinct residues to those phosphorylated in response to morphine binding to the receptor [28].
Conclusion

Continued opioid receptor signaling provides the engine for neuronal adaptations that are largely responsible for the whole animal phenomena of tolerance and dependence. Most evidence suggests that alterations in receptor signaling per se are limited in chronically agonist-treated animals, with limited evidence for alterations in the complement of G proteins activated by opioid receptors, or an increase in any non-G protein-mediated signaling. Acute opioid receptor phosphorylation is correlated with a reduction in receptor-signaling capacity, but there is no evidence that basal or agonist-induced μ-opioid receptor phosphorylation changes in chronically treated animals in vivo. μ-Opioid receptor-trafficking processes persist in chronically agonist-treated animals, and there are no good reasons to believe that receptor trafficking does anything other than resensitize or downregulate receptors in a manner similar to what has been observed in vitro.

Thus, to the extent that receptor phosphorylation and trafficking maintain signaling through the μ-opioid receptor, these two events are crucial in facilitating the adaptations to chronic opioid treatment. What remains to be established in vivo is just how important receptor trafficking is to maintaining receptor signaling in response to chronic treatment with pharmacologically relevant doses of drug. Despite the apparent failure of morphine to produce as much μ-opioid receptor phosphorylation or trafficking as some other agonists, it remains to be established that the neuronal adaptations produced by morphine are any different to those produced by other analgesic opioids such as methadone or fentanyl. Nevertheless, despite the identification of many adaptations to chronic opioid agonist treatment, the molecular mechanisms underlying even the most basic of these—the upregulation of neuronal adenyl cyclase activity—remain to be definitively established. Until more is known about how animals adapt to chronic opioid treatment, the possibility that agonist-specific phosphorylation or receptor trafficking can contribute to the induction or maintenance of different adaptations remains open.

Acknowledgments

Supported by NH&MRD of Australia Project Grant 302002 to M.C., and National Institute on Drug Abuse DA12926-01 to M.J.C. We thank Vu Dang for his helpful discussions.

References

Opioid Receptor Phosphorylation, Trafficking and Adaptation


70 Finn AK, Whistler JL: Endocytosis of the mu
65 Haberstock-Debic H, Kim K-A, Yu YJ, von
66 Haberstock-Debic H, Wein M, Barrot M, Co-
63 Borgland SL, Connor M, Osborne PB, Furness
68 Tanowitz M, von Zastrow M: A novel endo-
72 Bailey CP, Couch D, Johnson E, Griffiths K,
308: 512–517.
87 Drake CT, Aicher SA, Montaltm FL, Milner
308: 2684–2692.
80 Sim-Selley LJ, Selley DE, Vogt LJ, Childers
2684–2692.
81 Kirschke C, Schadrack J, Zieglauganberger W,
308: 43–51.
8204.
84 Liu JG, Ruckle MB, Prather PL: Constitutive
2684–2692.
85 Wang D, Raehul KM, Lin ET, Lowry JJ, Kief-
86 Trafton JA, Basbaum AI: [D-Ala2,N-
87 Drake CT, Aicher SA, Montalman FL, Milner
32–33.
88 Alvarez VA, Arttamangkul S, Dang V, Salem
20–23.
89 Terwilliger RZ, Ortiz J, Guitart X, Nestler EJ:
33–34.
90 Patel MB, Patel CN, Rajashekkara V, Yoburn
26–27.
91 Lefkowitz RJ, Shenoy S: Transduction of re-
146–187.
92 Dumont E, Williams JT: Noradrenaline trig-
93 Bhargava HN, Gulati A: Down-regulation of
70–73.
94 Christie MJ, Williams JT, North RA: Cellular
87–90.
95 Tao PL, Law PY, Loh HH: Decrease in delta
80–83.
96 Diaz A, Ruiz F, Florez J, Harle MA, Pazo A:
73–74.
97 Johnson/Christie/Connor
32–33.
98 Wang D, Raehul KM, Lin ET, Lowery JJ, Kief-
33–34.
99 Wang D, Raehul KM, Lin ET, Lowery JJ, Kief-
33–34.